


(Read and download) Intellectual Property, Pharmaceuticals and Public Health: Access to Drugs in Developing Countries

Intellectual Property, Pharmaceuticals and Public Health: Access to Drugs in Developing Countries

Kenneth C. Shadlen, Samira Guennif, Alenka Guzman, N. Lalitha
audiobook | *ebooks | Download PDF | ePub | DOC



 Download

 Read Online

#4820647 in Books 2013-07-31 Original language: English 9.25 x 6.25 x 1.00l, #File Name: 0857938797352 pages | File size: 67.Mb

Kenneth C. Shadlen, Samira Guennif, Alenka Guzman, N. Lalitha : Intellectual Property, Pharmaceuticals and Public Health: Access to Drugs in Developing Countries before purchasing it in order to gage whether or not it would be worth my time, and all praised Intellectual Property, Pharmaceuticals and Public Health: Access to Drugs in Developing Countries:

2 of 2 people found the following review helpful. Intellectual Property rights....By Phillip Taylor

MBE[[VIDEOID:mo1JBL3FVOGB9E]]MEET PUBLIC HEALTH WORLDWIDEAn appreciation by Phillip Taylor MBE and Elizabeth Taylor of Richmond Green ChambersPublished by Edward Elgar, this book will appeal strongly to a wide range of professionals, academics and students with interest in and involvement in public health issues worldwide, specifically the pharmaceutical industry.As the subtitle indicates, the focus here pertains to access to drugs in developing countries, an issue which has raised its profile in the public consciousness with increasing frequency, especially of late. To cite just one example, the book's four expert editors point out that post-Apartheid governments in South Africa have struggled with meeting the dual objectives of increasing local production of essential medicines, whilst reducing prices.Bearing all this in mind -- including the ongoing controversies centering on branded versus generic pharmaceutical products -- the pharmaceutical industry, which is concentrated mainly in only six countries, relies very much on patents and trademarks and is therefore heavily dependent on intellectual property rights, patents in particular.One assertion made by the editors, however -- all of whom hail from top universities worldwide, including the LSE and McGill -- is that the ongoing harmonization of IP rights globally over the last three or four decades, has meant that the pharmaceutical industry generally, has increased its presence in developing countries, both with respect to production and distribution.The 13 international contributors to this study - including the four editors - examine all pertinent aspects of this fascinating field, including the latest developments across at least eleven different countries. Case studies are presented of national experiences in Africa, Asia and the Americas, notably Canada. Pricing and drug registration policies, as well as patents and other regulatory instruments are systematically and methodically examined.Interestingly, the book is the ultimate result of a collaborative project entitled 'Globalisation and Public Health in Developing Countries' funded by the Foundation Maison des Sciences de l'Homme in Paris.For those involved in healthcare disciplines - and that includes lawyers with pharmaceutical clients - the book is timely, topical, and packed with carefully researched information which puts a number of major issues relating to pharmaceuticals in perspective. Of great value to researchers are the copious footnotes and extensive bibliographies which follow most of the articles.If you're a student, academic, or practitioner in related IP issues, particularly international health, international political economy, or international development and law, this book certainly provides you with an impressive mine of information if you find yourself having to argue your corner on any number of legal, economic and ethical issues in this complex field of study.

'Since the 1970s the pharmaceutical industry has undergone significant changes in its research and development paradigm, trade and production. Regulatory frameworks have also changed substantially, particularly in the area of intellectual property rights. This book provides much needed empirical evidence on the impact of these and other changes on the pharmaceutical sector and on access to medicines in developing countries. The studies, conducted with a common methodology, on nine developing countries (including major producers of pharmaceuticals such as China and India) and on Canada, make an outstanding contribution to the literature in the field. The data and analysis in the book are of immediate interest to policy makers and to scholars in various fields, including innovation economics, industrial policy, health systems and intellectual property.'- Carlos Correa, University of Buenos Aires, Argentina'This impressive collection offers fascinating new perspectives on the impact of pharmaceutical patents on access to medicines in developing countries. The volume's editors have put together an important book that sets out clearly the challenges to public health in a wide range of national contexts. The book will be a valuable text for all scholars and decision-makers interested in the global politics of intellectual property rights and public health.'- Duncan Matthews, Queen Mary, University of London, UKThis up-to-date book examines pharmaceutical development, access to medicines, and the protection of public health in the context of two fundamental changes that the global political economy has undergone since the 1970s, the globalization of trade and production and the increased harmonization of national regulations on intellectual property rights.With authors from eleven different countries presenting case studies of national experiences in Africa, Asia and the Americas, the book analyzes national strategies to promote pharmaceutical innovation, while at the same time assuring widespread access to medicines through generic pharmaceutical production and generic pharmaceutical importation. The expert chapters focus on patents as well as an array of regulatory instruments, including pricing and drug registration policies.Presenting in-depth analysis and original empirical research, this book will strongly appeal to academics and students of intellectual property, international health, international political economy, international development and law.Contributors: T. Andia, M. Bourassa Forcier, M. Flynn, P. Gehl Sampath, S. Guennif, A. Guzmán, H. Klug, G. Krikorian, N. Lalitha, J.-F. Morin, K.C. Shadlen, L. Shi, M. Watanabe

[T]his book will appeal strongly to a wide range of professionals, academics and students with interest in and involvement in public health issues worldwide, specifically the pharmaceutical industry... the book is timely, topical, and packed with carefully researched information which puts a number of major issues relating to pharmaceuticals in perspective. Of great value to researchers are the copious footnotes and extensive bibliographies which follow most of the articles... this book certainly provides you with an impressive mine of information if you find yourself having to

argue your corner on any number of legal, economic and ethical issues in this complex field of study. --Phillip Taylor MBE and Elizabeth Taylor, *The Barrister Magazine* About the Author Edited by Kenneth C. Shadlen, London School of Economics and Political Science, UK, Samira Guennif, Universite Paris 13, France, Alenka Guzman, Autonomous Metropolitan University-Iztapalapa, Mexico and N. Lalitha, Gujarat Institute of Development Research, India